Mitochondrial cofactor supplement · Fact sheet
Coenzyme Q10
Also known as CoQ10 · Ubiquinone · Ubiquinol
Coenzyme Q10 is a mitochondrial cofactor studied in several diseases. A heart-failure trial found an adjunctive clinical benefit, while a large Parkinson trial found no benefit. Those results do not establish general anti-aging or energy effects.
What is Coenzyme Q10?
Ubiquinone and ubiquinol are oxidized and reduced forms of CoQ10. Products and formulations vary.
A normal mitochondrial role is not evidence that extra supplementation improves health in everyone.
Benefits & claims
Interest in Coenzyme Q10 spans aging and energy, specific medical conditions. Study findings apply to the named formulation and population.
What the evidence supports
- Q-SYMBIO found fewer major cardiovascular events over two years, without significant short-term endpoint improvements.
- The Parkinson trial found no clinical benefit at either studied high daily amount.
- Condition-specific findings cannot establish universal longevity, fatigue or neurologic benefit.
Research areas
- Formulation-specific human outcomes
- Mechanistic research
Dosage & frequency
Human study contextThis is an exposure from a named human study, not a generally established treatment or enhancement regimen.
Q-SYMBIO randomized trial
Adults with moderate to severe chronic heart failure receiving standard therapy
- Amount
- 100 mg
- Frequency
- Three times daily for two years
- Route studied or labeled
- Oral
Adjunctive disease-specific research, not a replacement for heart-failure therapy or an anti-aging regimen. This amount does not establish equivalence among ubiquinone and ubiquinol preparations.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- Ubiquinone and ubiquinol are oxidized and reduced forms of CoQ10. Products and formulations vary.
Formulation differences
- A normal mitochondrial role is not evidence that extra supplementation improves health in everyone.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Reproducibility in larger independent trials
- Long-term outcomes and adverse effects
- Equivalence of different preparations and interaction profiles
Side effects & risks
- Digestive upset and insomnia may occur.
- CoQ10 can interact with warfarin and insulin; interactions with cancer treatments also require disease-specific assessment.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Moderate human evidenceQ-SYMBIO studied 420 people with chronic heart failure on standard therapy. The 600-person early-Parkinson trial stopped for futility despite favorable earlier signals.
Studies
420-person adjunctive heart-failure trial.
600-person early-Parkinson trial; stopped for futility.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
No FDA-approved Coenzyme Q10 drug indication is established for the supplement uses discussed here. Supplement availability is not FDA approval of efficacy or safety.
No FDA-approved product for this entry
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Reproducibility in larger independent trials
- Long-term outcomes and adverse effects
- Equivalence of different preparations and interaction profiles
Summary
Condition-specific findings cannot establish universal longevity, fatigue or neurologic benefit.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedThe effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial.
420-person adjunctive heart-failure trial.
- pubmedA randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.
600-person early-Parkinson trial; stopped for futility.
- nihNCCIH: coenzyme Q10
Condition-specific evidence, adverse effects and interactions including warfarin and insulin.